Status:

COMPLETED

Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112

Lead Sponsor:

National Institute of Mental Health (NIMH)

Conditions:

Healthy

Eligibility:

All Genders

Phase:

PHASE1

Brief Summary

This study will investigate the use of \[11C\]NNC-112 in positron emission tomography (PET) scanning. PET is a technique that uses radioactive isotopes called tracers to provide images of the brain. I...

Detailed Description

Abnormalities in dopaminergic neurotransmission have been implicated in several neurodegenerative and psychiatric disorders, such as Parkinson's disease, schizophrenia, attention-deficit-hyperactivity...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA
  • All subjects must be healthy and aged 18-70 years.
  • EXCLUSION CRITERIA
  • Current psychiatric disease, substance abuse or severe systemic disease based on history and physical exam
  • Laboratory tests with clinically significant abnormalities
  • More than moderate hypertension
  • Any prior participation in other research protocols within the past year that involve radiation, with the exception of plain radiography studies (i.e., chest x-rays).
  • Pregnancy and Breast Feeding
  • Positive HIV test

Exclusion

    Key Trial Info

    Start Date :

    July 1 2004

    Trial Type :

    INTERVENTIONAL

    End Date :

    March 1 2006

    Estimated Enrollment :

    10 Patients enrolled

    Trial Details

    Trial ID

    NCT00088517

    Start Date

    July 1 2004

    End Date

    March 1 2006

    Last Update

    March 4 2008

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institute of Mental Health (NIMH)

    Bethesda, Maryland, United States, 20892